Skip to main content

Table 1 (abstract P042). Disease and treatment characteristics stratified by ILAR classification. Values are median (IQR) or n (%). Medication use is in the 12 months after diagnosis. All p-values <0.0001

From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)

 

RF- poly JIA (n=171)

RF+ poly JIA (n=30)

Oligo JIA (n=243)

Other JIA (n=161)

Time (year) from diagnosis to 1st DMARD

0.01 (0, 0.09)

0.01 (0, 0.05)

0.31 (0.07, 1.21)

0.04 (0, 0.13)

cJADAS

16 (10.5, 20.5)

19 (15.5, 25)

7 (5, 10)

11 (7.5, 15)

AJC

8 (4, 10)

10 (7, 10)

1 (1, 2)

2 (1, 6)

Patient global

4 (2, 6)

5.5 (3, 7)

3 (1, 5)

4 (2, 6)

PGA

4 (2.5, 7)

5.5 (3, 8)

3 (1, 4)

3 (1.5, 5)

Joint injection

37 (22%)

9 (30%)

106 (44%)

41 (25%)

Glucocorticoids

80 (47%)

20 (67%)

68 (28%)

48 (30%)

nbDMARD >6 months

133 (78%)

23 (77%)

89 (37%)

79 (49%)

bDMARD >6 months

91 (53%)

20 (67%)

46 (19%)

82 (51%)